Onderneming Skye Bioscience, Inc. Other OTC
Aandelen
SKYE
US83086J1016
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Punit Dhillon
CEO | Chief Executive Officer | 44 | 19-01-18 |
Director of Finance/CFO | - | 05-10-21 | |
Chief Tech/Sci/R&D Officer | 52 | 13-12-22 | |
Karam Takhar
IRC | Investor Relations Contact | - | - |
Rhea Williams
LAW | General Counsel | - | 07-10-21 |
Tu Diep
PRN | Corporate Officer/Principal | 43 | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 77 | 07-08-20 | |
Praveen Tyle
BRD | Director/Board Member | 64 | 22-07-21 |
Andrew Schwab
BRD | Director/Board Member | 53 | 18-08-23 |
Paul Grayson
BRD | Director/Board Member | - | 18-08-23 |
Punit Dhillon
CEO | Chief Executive Officer | 44 | 19-01-18 |
Keith Ward
BRD | Director/Board Member | 54 | 14-12-21 |
Deborah Charych
BRD | Director/Board Member | - | 14-02-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 28 067 907 | 27 452 119 ( 97,81 %) | 0 | 97,81 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 46,56 mld. | |
+45,38% | 41,67 mld. | |
+0,69% | 41,16 mld. | |
+30,52% | 32,4 mld. | |
+22,30% | 28,18 mld. | |
-6,35% | 28,1 mld. | |
+49,25% | 14,52 mld. | |
+49,18% | 13,74 mld. | |
+3,45% | 12,17 mld. |